Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Maureen Riordan

Senior Deals Analyst

Connecticut, US
Maureen has been with Strategic Transactions for 20 years, first as a Research Analyst, now as a Senior Deals Analyst, with a brief in-between stint as Editor/Contributor for Start-Up company profiles. In her current role, she primarily researches, analyzes, writes, and edits summaries involving current biopharma and medtech deals – which appear in the ST database and the monthly dealmaking section of In Vivo – and also writes and updates legacy deals. Maureen regularly co-authors a quarterly statistics column covering deal trends in both the biopharma and medtech industries for In Vivo. Prior to joining Strategic Transactions, Maureen was a corporate librarian in a management consulting firm fielding search requests for in-house analysts, and then spent two years with Lexis-Nexis as a customer consultant having daily contact with client subscribers to teach database searching techniques. Maureen holds a Bachelor of Arts degree in English from Niagara University, and a Master of Library Science degree from Southern Connecticut State University.

Latest From Maureen Riordan

Financing Quarterly Statistics, Q2 2024

During Q2, biopharmas brought in an aggregate $22.8bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.2m.

Deals BioPharmaceutical

Deals in Depth: June 2024

Four $1bn+ alliances were penned in June. In the top alliance by deal value, Ascidian Therapeutics signed an agreement with Roche for the discovery and development of RNA exon editing therapeutics targeting neurological diseases. Roche received exclusive rights to Ascidian's RNA exon editing technology for undisclosed targets. Ascidian will conduct discovery and certain preclinical activities in collaboration with Roche, which will be responsible for certain preclinical activities, and further clinical development, manufacturing, and commercialization. Ascidian will receive an up-front payment of $42m as well as up to $1.8bn in research, clinical, and commercial milestone payments, as well as sales royalties.

Deals Financing

Deals in Depth: May 2024

Six $1bn+ alliances were penned in May. In the top alliance by deal value, AC Immune SA granted Takeda an option to license exclusive global rights to active immunotherapies targeting toxic forms of amyloid beta, including ACI-24.060 for the treatment of Alzheimer’s disease. AC Immune will receive $100m up front and is eligible to receive an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1bn, plus sales royalties.

Deals Financing

Deals in Depth: April 2024

Seven $1bn+ alliances were penned in April. In the top alliance by deal value, Medincell entered a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will receive a $35m upfront payment and is eligible to receive up to $1.9bn in development and commercial milestones, plus mid-single to low-double-digit royalties on net sales.

Deals Financing

Dealmaking Quarterly Statistics, Q1 2024

During Q1, biopharma merger and acquisition deal value reached $37bn, while the potential deal value from alliances was $38.5bn. Device company M&A values reached $3.6bn, while in vitro diagnostics and research tools players’ M&A activity totaled $1bn.

Deals Market Intelligence

Financing Quarterly Statistics, Q1 2024

During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.

Deals Financing
See All
UsernamePublicRestriction

Register